Max S. Topp
About
Max S. Topp is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Max S. Topp has authored 36 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pathology and Forensic Medicine, 15 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Max S. Topp's work include Lymphoma Diagnosis and Treatment (22 papers), Chronic Lymphocytic Leukemia Research (9 papers) and CAR-T cell therapy research (8 papers). Max S. Topp is often cited by papers focused on Lymphoma Diagnosis and Treatment (22 papers), Chronic Lymphocytic Leukemia Research (9 papers) and CAR-T cell therapy research (8 papers). Max S. Topp collaborates with scholars based in Germany, United States and Italy. Max S. Topp's co-authors include Andreas Engert, Peter Borchmann, Hermann Einsele, Johannes Duell, Bastian von Tresckow, Dennis A. Eichenauer, Gerhard Zugmaier, Georg Kuhnert, Markus Dietlein and Michael Fuchs and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
Max S. Topp
35 papers receiving 1.3k citations
Hit Papers
Peers
Max S. Topp
Wolfram Jung Germany
Johannes Duell Germany
Stephanie Sasse Germany
Oliver Manzke Germany
Ciara L. Freeman United States
Tom van Meerten Netherlands
Philipp Kiewe Germany
A H Goldstone United Kingdom
Manali Kamdar United States
KC Anderson United States
Citations per year, relative to Max S. Topp Max S. Topp (= 1×)
peers
Wolfram Jung
Countries citing papers authored by Max S. Topp
Since
Specialization
Citations
This map shows the geographic impact of Max S. Topp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max S. Topp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max S. Topp more than expected).
Fields of papers citing papers by Max S. Topp
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Max S. Topp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max S. Topp. The network helps show where Max S. Topp may publish in the future.
Co-authorship network of co-authors of Max S. Topp
This figure shows the co-authorship network connecting the top 25 collaborators of Max S. Topp. A scholar is included among the top collaborators of Max S. Topp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max S. Topp. Max S. Topp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lang, Fabian, Andreas Voß, Guido Kobbe, et al.. (2025). Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia & lymphoma. 66(6). 1079–1087.
2.
Kircher, Stefan, Katja Maurus, Max S. Topp, et al.. (2025). Fibrin-associated large B-cell lymphoma arising in a cystic lymphangiomatous lesion of the adrenal gland: A case report and overview of the entity. Pathology - Research and Practice. 270. 155957–155957.
3.
Duell, Johannes, et al.. (2024). Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies. Journal for ImmunoTherapy of Cancer. 12(12). e009174–e009174.
4.
Kosmala, Aleksander, Johannes Duell, Sebastian E. Serfling, et al.. (2023). Chemokine receptor–targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG. European Journal of Nuclear Medicine and Molecular Imaging. 51(3). 749–755.
5.
Duell, Johannes, Andreas Schirbel, Samuel Samnick, et al.. (2021). Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT. Journal of Nuclear Medicine. 62(10). 1415–1421.
6.
Goergen, Helen, Stefanie Kreissl, Annette Plütschow, et al.. (2021). Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group. Leukemia. 36(2). 580–582.
7.
Rosenwald, Andreas, Elena Hartmann, Anke Heidemeier, et al.. (2021). R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement. Journal of Cancer Research and Clinical Oncology. 148(1). 205–214.
8.
Plütschow, Annette, Michael Fuchs, Jana Marková, et al.. (2021). Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). The Lancet Haematology. 8(4). e278–e288.
9.
Fuchs, Michael, Carsten Kobe, Thomas Pabst, et al.. (2021). PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group. Blood. 138(Supplement 1). 2438–2438.
10.
Ghosh, Nilanjan, William Townsend, Michael Dickinson, et al.. (2021). Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study. Blood. 138(Supplement 1). 2479–2479.
11.
Kreissl, Stefanie, Horst Müller, Helen Goergen, et al.. (2020). Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group. Journal of Clinical Oncology. 38(25). 2839–2848.
12.
Kantarjian, Hagop, Elias Jabbour, & Max S. Topp. (2017). The authors and a colleague reply. New England Journal of Medicine. 376(23).
13.
Eichenauer, Dennis A., Annette Plütschow, Stefanie Kreissl, et al.. (2017). Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. The Lancet Oncology. 18(12). 1680–1687.
14.
Zinzani, Pier Luigi, Max S. Topp, Sam Yuen, et al.. (2016). Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine+Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data. Blood. 128(22). 617–617.
15.
Topp, Max S., Zachary Zimmerman, & Hagop M. Kantarjian. (2016). Correction regarding data on blinatumomab-associated seizures. Nature Reviews Clinical Oncology. 13(10). 650–650.
16.
Kantarjian, Hagop M., Anthony S. Stein, Ralf C. Bargou, et al.. (2016). Blinatumomab treatment of older adults with relapsed/refractory B‐precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer. 122(14). 2178–2185.
17.
Tresckow, Bastian von, Franck Morschhauser, Vincent Ribrag, et al.. (2015). An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clinical Cancer Research. 21(8). 1843–1850.
18.
Rasche, Leo, Johannes Duell, Valentina Dubljevic, et al.. (2015). GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. Haematologica. 100(3). 377–384.
19.
Zhukovsky, Eugene A., Achim Rothe, Bastian von Tresckow, et al.. (2013). A Phase I Study Of An Anti-CD30 x Anti-CD16A Bispecific Tandab Antibody, AFM13, In Patients With Relapsed Or Refractory Hodgkin Lymphoma. Blood. 122(21). 5116–5116.
20.
Spahn, Martin, et al.. (2010). The Worst Case: Giant Exulcerating Seminoma. Urologia Internationalis. 84(1). 113–115.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Wolfram Jung Breakdown of academic impact, for papers by Johannes Duell Breakdown of academic impact, for papers by Stephanie Sasse Breakdown of academic impact, for papers by Oliver Manzke Breakdown of academic impact, for papers by Ciara L. Freeman Breakdown of academic impact, for papers by Tom van Meerten Breakdown of academic impact, for papers by Philipp Kiewe Breakdown of academic impact, for papers by A H Goldstone Breakdown of academic impact, for papers by Manali Kamdar Breakdown of academic impact, for papers by KC Anderson